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Abstract
Background: Sentinel lymph node (SLN) biopsy is an effective tool for axillary staging in patients
with invasive breast cancer. This procedure has been recently proposed as part of the treatment
for patients with ductal carcinoma in situ (DCIS), because cases of undetected invasive foci and
nodal metastases occasionally occur. However, the indications for SLN biopsy in DCIS patients are
controversial.
The aim of the present study was therefore to assess the incidence of SLN metastases in a series
of patients with a diagnosis of pure DCIS.
Methods: A retrospective evaluation was made of a series of 102 patients who underwent SLN
biopsy, and had a final histologic diagnosis of pure DCIS. Patients with microinvasion were excluded
from the analysis. The patients were operated on in five Institutions between 1999 and 2004.
Subdermal or subareolar injection of 30–50 MBq of 99 m-Tc colloidal albumin was used for SLN
identification. All sentinel nodes were evaluated with serial sectioning, haematoxylin and eosin
staining, and immunohistochemical analysis for cytocheratin.
Results:  Only one patient (0.98%) was SLN positive. The primary tumour was a small
micropapillary intermediate-grade DCIS and the SLN harboured a micrometastasis. At pathologic
revision of the specimen, no detectable focus of microinvasion was found.
Conclusion: Our findings indicate that SLN metastases in pure DCIS are a very rare occurrence.
SLN biopsy should not therefore be routinely performed in patients who undergo resection for
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DCIS. SLN mapping can be performed, as a second operation, in cases in which an invasive
component is identified in the specimen. Only DCIS patients who require a mastectomy should
have SLN biopsy performed at the time of breast operation, since in these cases subsequent node
mapping is not feasible.
Background
Ductal carcinoma in situ (DCIS) is defined as the prolifer-
ation of malignant epithelial cells in the mammary ductal
system, with no evidence of invasion of the basement
membrane. By definition, the disease is localized to the
breast, with no spread to regional nodes or distant sites.
In the pre-mammography era, DCIS was rarely diagnosed,
accounting for only 1 to 2% of all breast cancers. The
increasing use of screening mammography in recent years
has resulted in a dramatic increase in the diagnosis of
DCIS, which now accounts for roughly 20% of all mam-
mographically detected cancers [1].
Axillary treatment in patients with a diagnosis of pure
DCIS is controversial. By definition, pure DCIS is not
invasive and cannot spread to the regional nodes, so axil-
lary staging should not be indicated in DCIS patients. In
practice, however, nodal metastases are found in 1 to 2%
of patients with a diagnosis of pure DCIS, and this para-
doxical condition usually depends on a focus of invasion
being missed by the pathologist because of a sampling
bias [2]. Before the introduction of sentinel lymph node
(SLN) biopsy, it was widely agreed that axillary lymph
node dissection (ALND) should be avoided in patients
with DCIS, because of the low yield of positive findings in
these cases and the significant morbidity associated with
the procedure [3]. The introduction of SLN biopsy as a
minimally invasive tool for staging the axilla led to a
renewed interest in axillary staging for these patients, for
two reasons. First, this procedure is far less invasive than
ALND and has minimal morbidity and complications, so
the cost/benefit ratio may be positive even if the likeli-
hood of finding metastatic nodes is low. Second, SLN
biopsy allows more accurate axillary staging than ALND
specimen examination, because SLN can be thoroughly
evaluated by serial sectioning and immunohistochemical
methods. This has led to the increased detection of nodal
micrometastases in patients with invasive breast cancer,
and has raised the expectation that the rate of positive
nodal findings in patients with DCIS could also be
increased. Currently, the indications for SLN biopsy in
patients with a diagnosis of pure DCIS are controversial.
The aim of the present study was to determine the preva-
lence of SLN metastasis in a multi-institutional series of
patients with a diagnosis of pure DCIS in order to deter-
mine the usefulness of routine SLN biopsy in such cases.
Methods
Patients
Our series consisted of 102 patients with a final his-
topathological diagnosis of pure DCIS who underwent
SLN biopsy in five Institutions between January 1999 and
January 2004. Patients with DCIS with microinvasion
were excluded from the study.
All patients underwent SLN biopsy after they had given
their written informed consent, and had decided whether
they would undergo a completion ALND if SLN were
found to be positive.
Lymphoscintigraphy
On the day before surgery, all the patients received an
injection of 30–50 MBq of 99 m-Tc-nanocolloidal albu-
min (Nanocoll, Nicomed-Italia, Saluggia, Italy) in 0.2 cc
of saline.
In patients with palpable tumours, the radiocolloid was
injected subdermally into the cutaneous projection of the
tumour. In those with non-palpable tumours, the lesion
was localized by stereotactic or ultrasonographic place-
ment of a self-retaining wire and the cutaneous projection
was marked by an ink spot on the skin, which served as a
guide for subdermal radiocolloid injection. Patients with
extensive microcalcifications or multifocal tumours were
given subareolar radiotracer injection. Finally, patients
who underwent delayed SLN biopsy after excision of the
primary lesion were given subdermal radiotracer injection
in two fractions, at the sides of the surgical scar.
Twenty minutes and 2 hours after injection, scintigraphic
images were obtained using a large-field-of-view gamma
camera (Orbiter, Siemens, IL, USA) equipped with a par-
allel hole, low energy and a high resolution collimator.
Surgical procedure
Primary tumour resection with simultaneous SLN biopsy
was performed in patients with a preoperative diagnosis
of DCIS made by stereotactically-guided directional vac-
uum-assisted biopsy and in those with mammographical
finding pathognomonic of DCIS, with or without a preop-
erative cytologic diagnosis of malignancy. A diagnostic
excisional biopsy was performed in patients with a doubt-
ful pre-operative diagnosis, and SLN biopsy was per-
formed as a second operation in those with a final
histologic diagnosis of DCIS.BMC Cancer 2005, 5:28 http://www.biomedcentral.com/1471-2407/5/28
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As a rule, in patients undergoing conservative surgery for
non-palpable lesions, an intraoperative x-ray examination
of the resected specimen was performed, in order to con-
firm that complete tumour excision had been achieved.
SLN biopsy was performed 16 to 24 hours after radiocol-
loid injection. When conservative surgery was performed,
the SLN was excised through the incision used for resect-
ing the primary tumour, if located in the upper outer
quadrant, whereas a separate axillary incision was per-
formed if the tumour was located in another breast site. A
gamma-ray-detecting probe was used for intraoperative
SLN identification. All lymph nodes with a probe-
detected radioactive count >10% of that of the hottest
node were excised.
Histopathology
The excised breast lesions were sampled with serial cuts
and the margins were identified by ink.
The histopathologic diagnosis and classification of DCIS
was made according to the Holland grading system [4].
The Van Nuys prognostic index [5] was used only in some
of the cases. The search for microinvasive foci was per-
formed in selected cases both with haematoxylin-eosin
serial sections and immunostains to smooth muscle actin
and CD10 for the detection of myoepithelial cells. In all
cases, the tumour size and margin status were specified in
the histopathological report. The SLN examination was
performed as described elsewhere [6]. Briefly, for frozen-
section examination, nodes with diameters of ≤  0.5 cm
were bisected, while nodes measuring >0.5 cm were sec-
tioned each 2 to 3 mm. For each sample, two frozen sec-
tions made at 40 µm intervals were examined. The frozen
tissue was then thawed, fixed and embedded to obtain
permanent sections.
For definitive histological examination, two consecutive 5
µm thick tissue sections were cut from a paraffin block at
two levels, 40 µm apart from each other. The sections were
then stained with haematoxylin-eosin and immunos-
tained with monoclonal antibody to cytokeratin.
Results
The 102 patients with pure DCIS had a median age of 59.4
years (range 37 to 85). The histologic characteristics of the
tumours are reported in Table 1.
Of the 102 patients, 20 (19.6%) had palpable, and 82
(80.4%) non-palpable breast tumours.
Seventy-four patients (72.5%) were treated with conserv-
ative surgery (quadrantectomy or lumpectomy) and 28
(27.5%) with mastectomy.
Ninety-one patients underwent primary tumour resection
with simultaneous SLN biopsy: 16 on the basis of a preop-
erative histologic diagnosis of DCIS obtained by a vac-
uum-assisted large core biopsy, 63 with a preoperative
cytology suggestive of malignancy and 12 only on the
basis of the mammographical findings alone.
Patients with a doubtful preoperative diagnosis under-
went excisional biopsy of the breast lesion, and the 11
patients with pure DCIS at definitive histology, under-
went SLN biopsy and, if required, definitive treatment of
the primary tumour as a second operation.
A total of 147 SLNs were identified and excised from the
102 patients: a single SLN was found in 61 cases (59.8%),
two SLNs in 37 (36.3%), and three SLNs in 4 (3.9%).
A positive SLN was found in one (0.98%) patient, who
had one micrometastases (0.6 mm) detected by haema-
toxylin-eosin staining. The pathologic review of the surgi-
cal specimen confirmed that the tumour had been
completely excised, and no microinfiltration was
detected. In this SLN positive case, the primary tumour
was a micropapillary DCIS, G2, with a diameter of 16
Table 1: Characteristics of pure DCIS diagnosed in 102 patients
PATIENTS
N%
HISTOLOGIC SUBTYPE
Comedo 42 41.2
Cribriform 16 15.7
Solid 17 16.7
Papillary 7 6.9
Micropapillary 6 5.9
Comedo and solid 5 4.9
Others 9 8.8
TUMOUR SIZE
0–5 mm 14 13.7
5–10 mm 40 39.2
10–15 mm 19 18.6
15–20 mm 14 13.7
20–30 mm 10 9.8
>30 mm 2 2.0
Unknown 3 2.9
TUMOUR GRADE
G1 21 20.6
G2 37 36.3
G3 44 43.1
TYPE OF SURGERY
Lumpectomy/quadrantectomy 74 72.5
Mastectomy 28 27.5BMC Cancer 2005, 5:28 http://www.biomedcentral.com/1471-2407/5/28
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mm. The patient did not undergone previous microbiopsy
or FNAC, and SLN biopsy was performed at the time of
the primary tumour excision. Completion ALND was not
performed.
Discussion
Indications for routine SLN biopsy in patients with a diag-
nosis of pure DCIS are still controversial. The first study
proposing SLN biopsy for DCIS patients came from the H.
Lee Moffitt Cancer Center in the year 2000 [7]: in a study
of 87 DCIS patients, 5 (5.7%) presented SLN metastases,
and the authors concluded that SLN biopsy should be
routinely used in DCIS patients in order to identify and
correctly stage patients with undetected invasive disease.
In a later report on 195 DCIS patients from the same Insti-
tution, 26 (13%) patients were SLN positive and this find-
ing strengthened the recommendation that SLN biopsy
should become a routine part of surgical treatment for all
DCIS patients [8].
The Memorial Sloan-Kettering Cancer Center group
reviewed patients with "high risk" DCIS and found that 9/
76 (12%) patients had SLNs positive for metastases. The
authors suggested that SLN biopsy should be performed
in all DCIS patients with one or more of the following
characteristics: palpable or mammographic mass, suspi-
cion of microinvasion, multicentric disease, high nuclear
grade or necrosis [9].
On the other hand, in subsequent studies negligible rates
of nodal involvement were found in patients with pure
DCIS: Kelly et al. [10] found nodal metastases in only 3/
134 (2.2%) patients, Intra et al. reported SLN metastases
in 7/223 (3.1%) patients [11], Farkas et al. found no cases
of SLN metastasis among 44 patients [12]. All these inves-
tigators concluded that SLN biopsy should not be rou-
tinely performed in patients with DCIS, with the
exception of those undergoing mastectomy, because this
operation precludes the possibility of performing a subse-
quent SLN biopsy if invasive foci are found at histology of
the mastectomy specimen. Our results are consistent with
the latter series of reports, since we found only one case of
SLN micrometastasis among 102 patients with a diagnosis
of pure DCIS (0.98%).
The variability in the reported rates of nodal metastases
probably reflects differences in the accuracy of pathologi-
cal evaluation of the primary breast tumour: extensive
sampling and a thorough histological examination of the
DCIS are of crucial importance in ruling out microinva-
sive foci. Microinvasive DCIS is a different pathological
entity, with a well-defined metastatic potential, and
should be excluded from studies evaluating the role of
axillary staging in non-invasive cancer.
Our results support the view that the presence of axillary
nodal metastases in patients with a final histopathological
diagnosis of pure DCIS is a very unusual phenomenon, if
the primary breast tumour has been completely excised
and thoroughly examined by the pathologist. We, there-
fore, believe that routine SLN biopsy in all DCIS patients
represents an over-treatment and should be avoided.
Enthusiasm for SLN biopsy in DCIS patients is partly due
to the low morbidity of the procedure. However, compli-
cations such as lymphedema, seroma, infection and sen-
sory neuropathy have been reported after SLN biopsy [13-
15]. Moreover, performing SLN biopsy in patients with a
small DCIS treated with a conservative operation pre-
cludes the possibility of using this procedure in patients
with a subsequent homolateral invasive tumour, which is
not infrequent in this setting [1].
Finally, the policy of performing primary tumour excision
with simultaneous SLN biopsy in all patients with a pre-
operative diagnosis of DCIS may incur a risk of perform-
ing axillary biopsy in patients with benign breast lesions,
since intraoperative frozen section histology is usually
unreliable in patients with small areas of
microcalcifications.
We therefore believe that this procedure should be used
cautiously, being reserved for cases in which a real advan-
tage can be expected.
Another factor that has prompted interest in SLN biopsy
for DCIS patients is the widespread use of image-guided
core needle biopsy for the diagnosis of mammographi-
cally-detected abnormalities, a diagnostic technique that
often fails to identify invasive foci: 14 to 29% of patients
with a preoperative core needle biopsy of DCIS are found
to have invasive cancer at surgical excision [16,17], and
require a second operation for axillary staging. With vac-
uum-assisted large core biopsy the under-diagnosis rate is
lower, but it is still not negligible. Supporters of routine
SLN biopsy claim that this procedure is not reliable after
primary tumour excision. They therefore believe that all
patients with a preoperative diagnosis of DCIS who
undergo definitive surgery and are upstaged because the
pathologist finds foci of invasion on the specimen, must
undergo an ALND if a SLN biopsy was not performed at
the time of the first operation [18]. We disagree with this
view, because it has been clearly demonstrated that SLN
biopsy can be safely performed as a second procedure
after primary tumour excision [19,20]. The only excep-
tions to this are patients who undergo mastectomy and
those who require a wide quadrantectomy of the upper
outer quadrant, which can disrupt lymphatic pathways
toward the axilla. We therefore believe that only patients
with a preoperative diagnosis of DCIS who need mastec-BMC Cancer 2005, 5:28 http://www.biomedcentral.com/1471-2407/5/28
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tomy or wide excision close to the axilla should undergo
a concomitant SLN biopsy. In all other cases, only the pri-
mary tumour excision should be performed and SLN
biopsy should be reserved, as a second procedure, for
patients found to have infiltration at the histologic exam-
ination of the primary tumour.
It has been claimed that some features of DCIS (large
dimensions, high grade, comedo-type, mass forming
lesions) are associated with a higher risk of invasive dis-
ease and nodal metastases. Therefore, some authors sug-
gest that SLN biopsy should be reserved for all patients
with these "high- risk" DCIS [9,21,22]. However, several
investigators fail to correlate any histopathologic parame-
ter with lymph node metastases [8,10,11].
The majority of patients in our series presented with low
risk DCIS: most of the tumours were small (<1 cm) and
only 20/102 patients had a palpable breast mass. There-
fore, we cannot rule out that a higher incidence of micro-
invasion and nodal metastases might be found in a
patient population with more aggressive forms of DCIS.
However, in our series, the one DCIS patient with SLN
metastasis had a small micropapillary, G2, non-palpable
tumour.
In our opinion, clinical judgement should be used in
patients with large solid tumours or diffuse comedo-type
DCIS, bearing in mind that most of these patients require
a mastectomy and are therefore candidates for SLN
biopsy.
Conclusion
Our results confirm that the finding of SLN metastasis in
pure breast DCIS is a very rare occurence, if the primary
tumour has been completely excised and microinvasion
has been ruled out by a thorough histologic examination.
Therefore, our current policy is to avoid routine SLN
biopsy at the time of primary tumour resection in the
presence of a preoperative diagnosis of DCIS. We reserve
this procedure, as a second operation, for cases in which
an invasive component is identified at the histologic
examination of the surgical specimen. Only patients with
a diagnosis of DCIS requiring a mastectomy or a wide
resection close to the axilla should undergo concomitant
SLN biopsy.
However, particularly if a large high-grade tumour is
found, patients should be informed of the risk that inva-
sive disease may be found, and that a second procedure
for SLN biopsy may be required. In these cases, the patient
can decide whether to undergo a potentially unnecessary
SLN biopsy at the time of the first operation or whether to
run the risk of requiring a second operation.
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